These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 34386358

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The epigenetic and transcriptional landscape of neuroendocrine prostate cancer.
    Davies A, Zoubeidi A, Selth LA.
    Endocr Relat Cancer; 2020 Feb; 27(2):R35-R50. PubMed ID: 31804971
    [Abstract] [Full Text] [Related]

  • 3. The Role of Epigenetic Change in Therapy-Induced Neuroendocrine Prostate Cancer Lineage Plasticity.
    Storck WK, May AM, Westbrook TC, Duan Z, Morrissey C, Yates JA, Alumkal JJ.
    Front Endocrinol (Lausanne); 2022 Feb; 13():926585. PubMed ID: 35909568
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Treatment-induced neuroendocrine prostate cancer and de novo neuroendocrine prostate cancer: Identification, prognosis and survival, genetic and epigenetic factors.
    Wishahi M.
    World J Clin Cases; 2024 May 06; 12(13):2143-2146. PubMed ID: 38808339
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Clinical and Biological Features of Neuroendocrine Prostate Cancer.
    Yamada Y, Beltran H.
    Curr Oncol Rep; 2021 Jan 12; 23(2):15. PubMed ID: 33433737
    [Abstract] [Full Text] [Related]

  • 12. The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer.
    Bishop JL, Thaper D, Vahid S, Davies A, Ketola K, Kuruma H, Jama R, Nip KM, Angeles A, Johnson F, Wyatt AW, Fazli L, Gleave ME, Lin D, Rubin MA, Collins CC, Wang Y, Beltran H, Zoubeidi A.
    Cancer Discov; 2017 Jan 12; 7(1):54-71. PubMed ID: 27784708
    [Abstract] [Full Text] [Related]

  • 13. MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer.
    Yasumizu Y, Rajabi H, Jin C, Hata T, Pitroda S, Long MD, Hagiwara M, Li W, Hu Q, Liu S, Yamashita N, Fushimi A, Kui L, Samur M, Yamamoto M, Zhang Y, Zhang N, Hong D, Maeda T, Kosaka T, Wong KK, Oya M, Kufe D.
    Nat Commun; 2020 Jan 17; 11(1):338. PubMed ID: 31953400
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Role of MicroRNAs in Neuroendocrine Prostate Cancer.
    Sreekumar A, Saini S.
    Noncoding RNA; 2022 Mar 30; 8(2):. PubMed ID: 35447888
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.